The US Food and Drug Administration is currently reviewing Biogen Idec's application for a fusion protein therapy designed to treat hemophilia B, the company said.
The company revealed that its drug, rFIXFc, has been designed to last longer than currently available drugs and allows patients to endure fewer treatments.
Advertisement
The FDA will be conducting a 10-month review of the drug and is expected to reach a decision in January next year.
Source: Medindia
Research Reveals Reasons for Severe Bleeding in Hemophilia
A study published by Cell Press on November 20 in the Biophysical Journal provides new insights into what causes uncontrollable bleeding in hemophilia patients.
Advertisement
 Effectiveness and Safety of New Treatment for Hemophilia Confirmed in Tulane-Led StudyA drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used for prevention of such events. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.